GR900100048A - Αντιμετώπιση ασθενειών σχετικών με μολύνσεις HΙV. - Google Patents

Αντιμετώπιση ασθενειών σχετικών με μολύνσεις HΙV.

Info

Publication number
GR900100048A
GR900100048A GR900100048A GR900100048A GR900100048A GR 900100048 A GR900100048 A GR 900100048A GR 900100048 A GR900100048 A GR 900100048A GR 900100048 A GR900100048 A GR 900100048A GR 900100048 A GR900100048 A GR 900100048A
Authority
GR
Greece
Prior art keywords
hiv
cysteine
treatment
diseases associated
pathogenesis
Prior art date
Application number
GR900100048A
Other languages
English (en)
Inventor
Wulf Droge
Leonard A Herzenberg
Leonore A Herzenberg
Original Assignee
Zampon Group S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zampon Group S P A filed Critical Zampon Group S P A
Publication of GR900100048A publication Critical patent/GR900100048A/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Ασθενείς που υποφέρουν από μόλυνση -ΗΙV υποβάλλονται σε αγωγή με Ν-(κατώτερο ακυλ)κυστεϊνη ένα αλάτι της, προς ανακούφιση των συμπτωμάτων και καταστολή της μεταγραφής και εξάπλωσης ΗΙV. Συγκεκριμένα, ενώσεις Ν-ακετυλκυστεΙνης χρησιμοποιούνται προς αντιμετώπιση των οροθετικών και με συμπτώματα ασθενών με ΑΙDS και προς ανακούφιση συμπτωμάτων όπως η απώλεια βάρους και απώλεια φυσικής δυνάμεως. Χρήση των ενώσεων Ν-ακετυλ κυστεϊνης σε συνδυασμό με φάρμακα που επηρεάζουν την παθογενεσία (παθογονία) των προκαλεσμένων από ΗΙV -ασθενειών, μπορεί να συμπληρώσουν τα αποτελέσματα παρόμοιων φαρμάκων. ω
GR900100048A 1989-01-26 1990-01-26 Αντιμετώπιση ασθενειών σχετικών με μολύνσεις HΙV. GR900100048A (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30239689A 1989-01-26 1989-01-26

Publications (1)

Publication Number Publication Date
GR900100048A true GR900100048A (el) 1991-06-07

Family

ID=23167578

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100048A GR900100048A (el) 1989-01-26 1990-01-26 Αντιμετώπιση ασθενειών σχετικών με μολύνσεις HΙV.

Country Status (25)

Country Link
US (1) US5607974A (el)
JP (1) JPH04504570A (el)
KR (1) KR940002820B1 (el)
AU (1) AU639686B2 (el)
BE (1) BE1004168A3 (el)
CA (3) CA1339070C (el)
CH (1) CH683499A5 (el)
DE (1) DE4090165T (el)
DK (1) DK139191A (el)
FR (1) FR2643557B1 (el)
GB (1) GB2243296B (el)
GR (1) GR900100048A (el)
IE (1) IE62795B1 (el)
IL (1) IL93162A (el)
IT (1) IT1237999B (el)
LU (1) LU87977A1 (el)
MA (1) MA21739A1 (el)
MX (1) MX173567B (el)
NL (1) NL9020094A (el)
OA (1) OA09503A (el)
PT (1) PT92949B (el)
SE (1) SE9101815D0 (el)
TN (1) TNSN90009A1 (el)
WO (1) WO1990008540A1 (el)
ZA (1) ZA90245B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205549A (es) * 1991-09-30 1993-05-01 Jess G Thoene Metodo para el tratamiento de vih.
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
EP0600462A1 (en) * 1992-12-01 1994-06-08 Nippon Flour Mills Co., Ltd. Reverse transcriptase inhibitors and antiviral agents
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
EP0789565A4 (en) * 1993-10-15 1999-03-24 Jess G Thoene PREVENTION OF HIV INFECTION
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
US5786152A (en) * 1996-04-26 1998-07-28 Amgen Inc. Methods of inhibiting syp binding to a CTLA-4 receptor
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
TW517089B (en) 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
US20050070607A1 (en) * 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP5027512B2 (ja) 2003-11-14 2012-09-19 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫調節法
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20070053970A1 (en) * 2005-05-25 2007-03-08 Guilford F T Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158487A2 (en) * 1984-04-09 1985-10-16 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
WO1988009674A1 (en) * 1987-06-09 1988-12-15 Biogen, Inc. Stabilized formulations of gamma interferons

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4767785A (en) * 1984-01-18 1988-08-30 Michael Georgieff Hypocaloric preparation and intravenous method for hypocaloric treatment of patients
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
DE3707127C2 (de) * 1987-03-05 1996-06-20 Zambon Spa Verwendung von Methionin zur Behandlung von Immun-Schwächeerkrankungen bei Virusinfektionen und/oder bei Tumorerkrankungen
DE3812008A1 (de) * 1987-04-10 1988-10-20 Pfrimmer Pharma Verwendung von l-(-)-thiazolidin-4-carbonsaeure als cysteinquelle bei gestoerter cysteinsynthese
DE3906671A1 (de) * 1989-03-02 1990-09-06 Wulf Prof Dr Droege Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158487A2 (en) * 1984-04-09 1985-10-16 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
WO1988009674A1 (en) * 1987-06-09 1988-12-15 Biogen, Inc. Stabilized formulations of gamma interferons

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLAIMS SEARCHED: ALL *
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 77, no. 1, July 1989, pages 7-10; J. WU et al.: "2-Mecaptoethanol and n-acetylcysteine enhance T cell colony formation in AIDS and ARC" *

Also Published As

Publication number Publication date
OA09503A (en) 1992-11-15
PT92949A (pt) 1990-07-31
KR910700045A (ko) 1991-03-13
MX173567B (es) 1994-03-16
IL93162A0 (en) 1990-11-05
IE900073L (en) 1990-07-26
GB2243296B (en) 1992-10-21
GB2243296A (en) 1991-10-30
CA2045180A1 (en) 1990-07-27
CH683499A5 (it) 1994-03-31
CA1339070C (en) 1997-07-29
JPH04504570A (ja) 1992-08-13
WO1990008540A1 (en) 1990-08-09
IE62795B1 (en) 1995-03-08
SE9101815L (sv) 1991-06-13
MA21739A1 (fr) 1990-10-01
FR2643557B1 (fr) 1995-02-03
AU4969490A (en) 1990-08-24
ZA90245B (en) 1990-10-31
NL9020094A (nl) 1991-10-01
AU639686B2 (en) 1993-08-05
PT92949B (pt) 1995-12-29
US5607974A (en) 1997-03-04
IT9019141A1 (it) 1991-07-24
LU87977A1 (fr) 1992-03-11
DK139191D0 (da) 1991-07-25
DK139191A (da) 1991-07-25
IT9019141A0 (it) 1990-01-24
IL93162A (en) 1995-03-15
TNSN90009A1 (fr) 1991-03-05
BE1004168A3 (fr) 1992-10-06
CA1339256C (en) 1997-08-12
KR940002820B1 (ko) 1994-04-04
GB9112420D0 (en) 1991-07-31
SE9101815D0 (sv) 1991-06-13
DE4090165T (el) 1991-11-21
FR2643557A1 (fr) 1990-08-31
IT1237999B (it) 1993-06-21

Similar Documents

Publication Publication Date Title
GR900100048A (el) Αντιμετώπιση ασθενειών σχετικών με μολύνσεις HΙV.
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
TR199903053T2 (xx) Benzimidazol t�revleri.
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
DK602988A (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
ES2051641B1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
DE69230643T2 (de) Methode zur behandlung von viralen infektionen
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
MX9700414A (es) Agentes antivirales de difluoroestatona.
NO981898D0 (no) Anvendelse av flupirtin for forhindring og behandling av sykdommer som er forbundet med skade pÕ det hematopotiske cellesystem
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
ATE189460T1 (de) Gegen protozoen wirksamezyklische tetrapeptide
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
CY1109771T1 (el) Η χρηση της φορμοτερολης στην προφυλακτικη και/ή θεραπευτικη αντιμετωπιση της μυικης απωλειας και/ή του καχεκτικου συνδρομου τα οποια συνδεονται με τις καταβολικες συνθηκες ορισμενων παθησεων. οπως ο καρκινος, to aids, οι μολυνσεις, ο διαβητης και αλλες
DK0428105T3 (da) Anvendelse af quinolyl- og isoquinolyloxazol-2-oner til fremstilling af et lægemiddel til hindring af infektioner med vira omhyllet med glycoprotein
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
DE69010736D1 (de) Anti-HIV Zusammensetzungen.
HRP20030701A2 (en) Natural antibodies active against hiv virus
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
RU96114547A (ru) Способ повышения активности систем неспецифической биологической защиты организма
FI963073A (fi) Makrosykliset difluorisatonijohdannaiset, jotka ovat käyttökelpoisia viruksia vastustavina aineina
RU93051046A (ru) Способ борьбы с аскосферозом и гнильцовыми болезнями пчел